FDA Accepts Novo Nordisk’s Resubmissions for Review of Tresiba, Ryzodeg

Drug Industry Daily
A A
Novo Nordisk is moving forward two years after the FDA rejected two insulin therapies, with the agency’s agreement to review Class II resubmissions of its NDAs for Tresiba and Ryzodeg drugs based on an interim analysis of data from a cardiovascular outcomes study.

To View This Article:

Login

Subscribe To Drug Industry Daily